IDT Australia Limited (IDT) AI Stock Analysis

• Market Cap: AU$20.97M
• Dividend Yield: N/A
• Average Volume (3M): 336.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 45.30%
• EPS Growth: -24.18%
• Country: AU
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 427,425,570
• 10 Day Avg. Volume: 373,970
• 30 Day Avg. Volume: 336,941
• PEG Ratio: -0.21
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.92
• P/FCF Ratio: -5.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: AU$0.05 ▲(0.00% Upside)

IDT Australia Limited's overall stock score is significantly impacted by its weak financial performance, characterized by consistent losses and negative cash flows. The technical analysis further supports a bearish outlook, with the stock trading below key moving averages and indicators showing oversold conditions. Additionally, the negative P/E ratio and lack of dividend yield make the stock unattractive from a valuation standpoint. Without positive earnings call insights or notable corporate events, the stock remains a high-risk investment.

Positive Factors

Revenue Growth

Despite financial challenges, the company has managed to achieve revenue growth, indicating potential market demand and operational resilience.

Diverse Revenue Streams

The company's diverse revenue streams from contract manufacturing and proprietary products provide a buffer against market volatility and enhance growth potential.

Stable Asset Base

A stable asset base relative to equity indicates financial stability, which can support long-term strategic initiatives and growth.

Negative Factors

Negative Cash Flows

Negative cash flows pose liquidity risks, limiting the company's ability to invest in growth opportunities and potentially impacting its financial stability.

Profitability Challenges

Ongoing profitability challenges hinder the company's ability to generate sustainable earnings, affecting its long-term viability and investor confidence.

Increased Leverage

Increased leverage can strain financial resources, reducing flexibility and increasing risk, especially if revenue growth does not offset the debt burden.

IDT Australia Limited Business Overview & Revenue Model

Company Description

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.

How the Company Makes Money

IDT generates revenue through multiple streams, primarily from contract manufacturing services for pharmaceutical companies, which involves producing drugs on behalf of clients. This includes the formulation and production of both generic and branded medications. Additionally, IDT earns income from its proprietary product development, where it develops its own drugs and seeks to commercialize them. Partnerships with other pharmaceutical firms enhance its revenue potential, as IDT often collaborates on product development and manufacturing agreements. The company also benefits from government and regulatory approvals which can bolster its market position and drive sales. Overall, IDT's revenue model is heavily reliant on its ability to secure and maintain contracts with pharmaceutical clients, along with successful product launches in the market.

IDT Australia Limited Financial Statement Overview

Summary

IDT Australia Limited is facing significant financial challenges, with consistent losses and negative cash flows. While there is some revenue growth, profitability and liquidity issues are prominent. The balance sheet shows increased leverage, which could pose risks if not managed carefully. Overall, the financial health of the company is weak, and strategic changes may be needed to improve performance.

Income Statement

IDT Australia Limited has shown some revenue growth, with a 5.28% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has also declined compared to previous years, suggesting challenges in cost management or pricing power.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but it remains relatively low compared to industry standards. The return on equity is negative, reflecting ongoing losses. However, the equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

IDT Australia Limited's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. This poses liquidity risks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.77M	19.77M	13.23M	6.93M	12.11M	15.99M
Gross Profit	9.69M	9.69M	10.42M	-3.53M	2.82M	4.88M
EBITDA	-6.54M	-6.54M	-5.56M	-8.83M	-340.00K	2.75M
Net Income	-8.06M	-8.06M	-5.41M	-8.50M	-1.16M	2.10M
Balance Sheet
Total Assets	36.92M	36.92M	31.37M	28.29M	30.08M	34.13M
Cash, Cash Equivalents and Short-Term Investments	4.11M	4.11M	904.00K	4.43M	9.21M	6.93M
Total Debt	10.40M	10.40M	4.47M	740.00K	881.00K	766.00K
Total Liabilities	15.03M	15.03M	7.93M	4.15M	3.46M	6.51M
Stockholders Equity	21.89M	21.89M	23.44M	24.14M	26.63M	27.61M
Cash Flow
Free Cash Flow	-7.55M	-7.55M	-10.30M	-8.42M	1.95M	-156.00K
Operating Cash Flow	-6.25M	-6.25M	-9.60M	-7.90M	2.86M	370.00K
Investing Cash Flow	-4.50M	-4.50M	-1.09M	-522.00K	-912.00K	-526.00K
Financing Cash Flow	10.75M	10.75M	6.77M	3.64M	337.00K	224.00K

IDT Australia Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 31.44 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$39.10M	10.93	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXS	48 Neutral	AU$42.43M	-2.91	-289.70%	―	-4.27%	33.91%
MVP	46 Neutral	AU$62.53M	545.00	0.19%	―	17.82%	―
IDT	37 Underperform	AU$20.97M	-2.68	-35.58%	―	45.30%	-24.18%

IDT Australia Limited Corporate Events

IDT Australia Cancels 164,000 Shares After Conditional Rights Lapse

IDT Australia Limited has announced the cessation of 164,000 ordinary fully paid shares following the lapse of conditional rights to these securities, after the specified conditions were not met or became incapable of being satisfied as of 29 September 2025. The reduction in potential issued capital reflects the non-vesting of these conditional rights, which may marginally affect future dilution expectations for existing shareholders but does not alter the company’s current issued share capital structure.

The most recent analyst rating on (AU:IDT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.

IDT Australia Director Increases Shareholding

IDT Australia Limited announced a change in the director’s interest, with Geoffrey Sam acquiring 98,039 ordinary fully paid shares through an on-market trade. This acquisition reflects a direct interest change and indicates a potential increase in confidence or strategic positioning by the director within the company.

The most recent analyst rating on (AU:IDT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.

IDT Australia Limited Successfully Concludes Annual General Meeting

IDT Australia Limited announced the results of its Annual General Meeting, where all resolutions were successfully carried. Key resolutions included the adoption of the remuneration report, the re-election of Dr. Jane Ryan as a director, and the approval of increased placement capacity. These outcomes reflect strong shareholder support and are likely to positively impact the company’s governance and operational capacity.

IDT Australia Limited’s Cautious Approach in AGM Presentation

IDT Australia Limited’s recent presentation at their Annual General Meeting emphasized the general nature of the information provided, highlighting that it is not intended for investment decision-making. The release underscores the inherent risks and uncertainties in the pharmaceutical industry and advises stakeholders to conduct independent assessments. The company stresses that the presentation is not a financial offer or solicitation, and any forward-looking statements are subject to change without obligation for updates.

IDT Australia Limited Announces Cessation of Securities

IDT Australia Limited announced the cessation of 2,155,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.

IDT Australia Announces Strategic Realignment and Cost Savings for FY26

IDT Australia Limited has announced a strategic realignment to focus on higher-return core business activities, resulting in anticipated annual cost savings of approximately $1 million for FY26. The company is shifting its Specialty Orals vertical towards radiopharmaceuticals, supported by recent contract wins, while maintaining its presence in clinical-stage innovations. Despite a Q1 EBITDA loss of $0.3 million, IDT reported a revenue increase of 18.2% from its three verticals compared to the previous year, driven by strong market demand and new contracts worth $3.4 million. This strategic shift aims to enhance profitability and leverage the company’s operational strengths.

IDT Australia Limited Announces Hybrid Annual General Meeting

IDT Australia Limited has announced its Annual General Meeting (AGM) scheduled for 19 November 2025, which will be conducted as a hybrid meeting allowing both in-person and virtual attendance. This meeting is significant for shareholders as it provides an opportunity to engage with the company’s board and participate in decision-making processes, reflecting IDT’s commitment to transparency and shareholder involvement.